Sign inCreate account

Report workspace tools

NCT04467983ACTIVE_NOT_RECRUITINGanonymous

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Sponsor

Source record

Hospital for Special Surgery, New York

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteoporosis, Postmenopausal

Indication / condition

AI-normalized

Osteoporosis, Postmenopausal

Intervention

Source record

Denosumab Injection, Abaloparatide

Source & freshness

Source record

NCT ID

NCT04467983

Original source

ClinicalTrials.gov

Source last updated

May 02, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04467983

Title

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Sponsor

Hospital for Special Surgery, New York

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Condition raw

Osteoporosis, Postmenopausal

Condition normalized

Osteoporosis, Postmenopausal

Modality raw

Osteoporosis, Postmenopausal

Modality normalized

monoclonal antibody

Target raw

Osteoporosis, Postmenopausal

Target normalized

Osteoporosis, Postmenopausal

Interventions

Denosumab Injection, Abaloparatide

Public preview

Source record

This clinical trial evaluates the efficacy of adding abaloparatide to ongoing denosumab treatment in postmenopausal women with osteoporosis. The study aims to determine if this combination therapy can improve bone mineral density (BMD) compared to continued denosumab alone. The trial is sponsored by the Hospital for Special Surgery in New York, with collaboration from Radius Health, Inc.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04467983

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Sponsor

Hospital for Special Surgery, New York

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy of adding abaloparatide to ongoing denosumab treatment in postmenopausal women with osteoporosis. The study aims to determine if this combination therapy can improve bone mineral density (BMD) compared to continued denosumab alone. The trial is sponsored by the Hospital for Special Surgery in New York, with collaboration from Radius Health, Inc.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 02, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04467983

Indication

Osteoporosis, Postmenopausal

Modality

monoclonal antibody

Target

Osteoporosis, Postmenopausal

Intervention

Denosumab Injection, Abaloparatide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.